A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 4202 participants.

Also called NCT01703208

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,202 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01703208
  • EudraCT 2012-002414-39
Other papers using this trial's data
  • A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus Cardiovascular diabetology, 2017-09-11 DOI, PubMed 28893244, PMC5594521 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01703208. Randomized; triple masking; primary purpose treatment. Start 2012-10-05 (actual); primary completion 2016-05-13 (actual). Results posted on 2017-12-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Omarigliptin
Intervention (Drug)
Placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01703208
Content hash
2515ad2959309b3a13d46f28fe190e677da539d6d1287359eea24c93dbb01f51